Literature DB >> 18347210

Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences.

Brett Burstein1, Eric Libby, Angelino Calderone, Stanley Nattel.   

Abstract

BACKGROUND: In various heart disease paradigms, atria show stronger fibrotic responses than ventricles. The possibility that atrial and ventricular fibroblasts respond differentially to pathological stimuli has not been examined. METHODS AND
RESULTS: We compared various morphological, secretory, and proliferative response indexes of canine atrial versus ventricular fibroblasts. Cultured atrial fibroblasts showed faster cell surface area increases, distinct morphology at confluence, and greater alpha-smooth muscle actin expression than ventricular fibroblasts. Atrial fibroblast proliferation ([(3)H]thymidine incorporation) responses were consistently greater for a range of growth factors, including fetal bovine serum, platelet-derived growth factor (PDGF), basic fibroblast growth factor, angiotensin II, endothelin-1, and transforming growth factor-beta(1). Normal atrial tissue showed larger myofibroblast density compared with ventricular tissue, and the difference was exaggerated by congestive heart failure. Congestive heart failure atria showed larger fractions of fibroblasts in mitotic phases compared with ventricles and displayed enhanced gene expression of fibroblast-selective markers (collagen-1, collagen-3, fibronectin-1). Gene microarrays revealed 225 differentially expressed transcript probe sets between paired atrial and ventricular fibroblast samples, including extracellular matrix (eg, fibronectin, laminin, fibulin), cell signaling (PDGF, PDGF receptor, angiopoietin, vascular endothelial growth factor), structure (keratin), and metabolism (xanthine dehydrogenase) genes, identifying PDGF as a candidate contributor to atrial-ventricular fibroblast differences. PDGF receptor gene expression was greater in normal atrium compared with ventricle, and congestive heart failure differentially enhanced atrial versus ventricular PDGF and PDGF receptor gene expression. PDGF receptor protein expression and alpha-smooth muscle actin protein expression were enhanced in isolated congestive heart failure fibroblasts. The PDGF receptor tyrosine kinase inhibitor AG1295 eliminated fetal bovine serum- and transforming growth factor-beta(1)-stimulated atrial-ventricular fibroblast proliferative response differences.
CONCLUSIONS: Atrial fibroblasts behave differently than ventricular fibroblasts over a range of in vitro and in vivo paradigms, with atrial fibroblasts showing enhanced reactivity that may explain greater atrial fibrotic responses. PDGF signaling is particularly important for atrium-selective fibroblast responses and may represent a novel target for arrhythmogenic atrial structural remodeling prevention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347210     DOI: 10.1161/CIRCULATIONAHA.107.748053

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  104 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

Review 3.  Origin of cardiac fibroblasts and the role of periostin.

Authors:  Paige Snider; Kara N Standley; Jian Wang; Mohamad Azhar; Thomas Doetschman; Simon J Conway
Journal:  Circ Res       Date:  2009-11-06       Impact factor: 17.367

Review 4.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

Review 5.  Transient receptor potential (TRP) channels and cardiac fibrosis.

Authors:  Zhichao Yue; Yanhui Zhang; Jia Xie; Jianmin Jiang; Lixia Yue
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 6.  Cross talk between cardiac myocytes and fibroblasts: from multiscale investigative approaches to mechanisms and functional consequences.

Authors:  P Zhang; J Su; U Mende
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-12       Impact factor: 4.733

7.  A distinct de novo expression of Nav1.5 sodium channels in human atrial fibroblasts differentiated into myofibroblasts.

Authors:  Aurélien Chatelier; Aurélie Mercier; Boris Tremblier; Olivier Thériault; Majed Moubarak; Najate Benamer; Pierre Corbi; Patrick Bois; Mohamed Chahine; Jean François Faivre
Journal:  J Physiol       Date:  2012-07-16       Impact factor: 5.182

8.  Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-β1.

Authors:  Dolkun Rahmutula; Gregory M Marcus; Emily E Wilson; Chun-Hua Ding; Yuanyuan Xiao; Agnes C Paquet; Rebecca Barbeau; Andrea J Barczak; David J Erle; Jeffrey E Olgin
Journal:  Cardiovasc Res       Date:  2013-04-23       Impact factor: 10.787

9.  Increased Susceptibility to Atrial Fibrillation Secondary to Atrial Fibrosis in Transgenic Goats Expressing Transforming Growth Factor-β1.

Authors:  Irina A Polejaeva; Ravi Ranjan; Christopher J Davies; Misha Regouski; Justin Hall; Aaron L Olsen; Qinggang Meng; Heloisa M Rutigliano; Derek J Dosdall; Nathan A Angel; Frank B Sachse; Thomas Seidel; Aaron J Thomas; Rusty Stott; Kip E Panter; Pamela M Lee; Arnaud J Van Wettere; John R Stevens; Zhongde Wang; Rob S MacLeod; Nassir F Marrouche; Kenneth L White
Journal:  J Cardiovasc Electrophysiol       Date:  2016-08-30

10.  Chronic hypoxia inhibits MMP-2 activation and cellular invasion in human cardiac myofibroblasts.

Authors:  Kirsten Riches; Michael E Morley; Neil A Turner; David J O'Regan; Stephen G Ball; Chris Peers; Karen E Porter
Journal:  J Mol Cell Cardiol       Date:  2009-06-11       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.